

Join Us for a Live Interactive CME Webcast!

Cross-Setting Strategies for Improved Identification, Diagnosis, and Management of Homozygous Familial Hypercholesterolemia

Thursday,
November 16, 2023
6:00 PM CT

Register NOW!

<https://wcacc.org/meet-reg1.php?id=6>

Faculty Presenter



Christie M. Ballantyne, MD, FACP, FACC

Professor of Medicine
Chief, Section of Cardiovascular Research
Department of Medicine
Director
Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, Texas

Program Overview

Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C), leading to premature cardiovascular disease. Affected individuals are typically less responsive or unresponsive to standard lipid-lowering therapies (ie, statins and PCSK9 inhibitors) and may benefit from treatments with alternative mechanisms of action, such as the recently FDA-approved ANGPTL3 inhibitor evinacumab. With this in mind, this program has been designed to educate clinicians about the prevalence of HoFH, the importance of HoFH screening, and the benefits and limitations of current therapies for lipid management in patients with the disease. The nationally recognized expert faculty will also provide practical advice to attendees, based on their personal success, regarding strategies that improve patient access to newer lipid-lowering therapies.

Target Audience

This educational activity has been designed for US cardiologists and internal medicine physicians, nurse practitioners, and physician assistants involved in the identification, diagnosis, and management of patients with HoFH.

Contact Information

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com

Learning Objectives

Upon completion of this educational activity, participants should be able to:

- Contrast the estimated prevalence versus the number of patients diagnosed with familial hypercholesterolemia (FH)
- Apply knowledge of cardinal symptoms and strategies for early identification of HoFH
- Employ cascade screening to ensure case identification in first degree relatives of patients with HoFH
- Discuss the role of LDLR-independent treatment strategies for patients with HoFH
- Utilize currently available therapies for appropriate treatment of patients with HoFH

Accreditation



Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation



Integrity Continuing Education, Inc. designates this live activity for a maximum of **1.0 AMA PRA Category 1 Credit™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions to Receive Credit

There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

- Complete the pretest
- Attend the live webcast
- Complete the posttest and evaluation form at the end of the program

Certificates will be sent via email within four weeks of receipt of the completed evaluation form.